ArticleBritish journal of cancer2012
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Combining the optimization of the CT examination process with a vial sharing strategy for contrast agents: an economical and practical method for hospitals.BMC health services research · 2026Article
- Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine.Clinical pharmacokinetics · 2025Review
- Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine.Heliyon · 2024Review
- An improvement of body surface area formulas using the 3D scanning technique.International journal of occupational medicine and environmental health · 2024Article
- Article
- Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors.Cancer chemotherapy and pharmacology · 2022Observational
- Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology.Endocrinology · 2022Review
- Dorsal Root Ganglion Morphometric Changes Under Oxaliplatin Treatment : Longitudinal Assessment by Computed Tomography.Clinical neuroradiology · 2022Article
- Review
- Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.Pharmacology research & perspectives · 2021Review
- Review
- Implementation and microbiological stability of dose-banded ganciclovir infusion bags prepared in series by a robotic system.European journal of hospital pharmacy : science and practice · 2020Article
- 'The same old story': thoughts on authorized doses of anticancer drugs.Therapeutic advances in medical oncology · 2020Article
- Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2019Observational
- Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition.Current opinion in supportive and palliative care · 2018Review
- The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University Hospital.European journal of hospital pharmacy : science and practice · 2018Article
- Exploratory analysis for the implementation of antineoplastic logarithmic dose banding.International journal of clinical pharmacy · 2018Article
- Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.British journal of clinical pharmacology · 2018Article
- Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.European journal of cancer (Oxford, England : 1990) · 2018Article
- 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDose banding is a recently suggested dosing method that uses predefined ranges (bands) of body surface area (BSA) to calculate each patient's dose by using a single BSA-value per band. Thus, drugs with sufficient long-term stability can be prepared in advance. The main advantages of dose banding are to reduce patient waiting time and improve pharmacy capacity planning; additional benefits include reduced medication errors, reduced drug wastage, and prospective quality control. This study compares dose banding with individual BSA dosing and fixed dose according to pharmacokinetic criteria.
methodsThree BSA bands were defined: BSA<1.7 m(2), 1.7 m(2)≤ BSA<1.9 m(2), BSA ≥ 1.9 m(2) and each patient dose was calculated based on a unique BSA-value per band (1.55, 1.80, and 2.05 m(2), respectively). By using individual clearance values of six drugs (cisplatin, docetaxel, paclitaxel, doxorubicin, irinotecan, and topotecan) from 1012 adult cancer patients in total, the AUCs corresponding to three dosing methods (BSA dosing, dose banding, and fixed dose) were compared with a target AUC for each drug.
resultsFor all six drugs, the per cent variation in individual dose obtained with dose banding compared with BSA dosing ranged between -14% and +22%, and distribution of AUC values was very similar with both dosing methods. In terms of reaching the target AUC, there was no significant difference in precision between dose banding and BSA dosing, except for paclitaxel (32.0% vs 30.7%, respectively; P<0.05). However, precision was significantly better for BSA dosing compared with fixed dose for four out of six drugs.
conclusionFor the studied drugs, implementation of dose banding should be considered as it entails no significant increase in interindividual plasma exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.